A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

Advances in Therapy - United States
doi 10.1007/s12325-020-01242-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Exenatide Extended-Release: A Once Weekly Treatment for Patients With Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2014English

Pdb67 - Once-Weekly Semaglutide Versus Dulaglutide for the Treatment of Patients With Type 2 Diabetes in Portugal: A Long-Term Cost-Effectiveness Analysis Based on Sustain 7

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pdb87 - A Cost-Of-Control Analysis: Once-Weekly Semaglutide Reduces Cost of Reaching Treatment Targets in Patients With Type 2 Diabetes Mellitus in Norway

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today
2014English

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2010English

Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Journal of Diabetes Research
EndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy